SCHEMBL23948590

SCHEMBL23948590

COc1ccoc1CCCN

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 6/20 0.39
KDM4E B2RXH2 1/20 0.38
ATM Q13315 1/20 0.38
HTR2A P28223 2/20 0.36
HTR2C P28335 2/20 0.36
TSHR P16473 2/20 0.36
MAPK1 P28482 1/20 0.36
ADRA1A P35348 1/20 0.36
HTR2B P41595 1/20 0.35
LMNA P02545 3/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
NFKB1 P19838 1/20 0.35
GLA P06280 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
APEX1 P27695 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23948511 0.93 CHRM2 (0.38) TAAR1KDM4EATMTSHRMAPK1
Acetic Acid SCHEMBL23925788 0.85 ACHE (0.36) TAAR1TSHRMAPK1
SCHEMBL21954486 0.80
SCHEMBL23948510 0.79 TNKS2 (0.37) KDM4EMAPK1HTR2BLMNACYP3A4
SCHEMBL30390536 0.79 HMGCR (0.37) KDM4EHTR2ALMNACYP3A4MEN1
SCHEMBL3342032 0.77 PTGS2 (0.37) TAAR1KDM4ETSHRMAPK1LMNA
SCHEMBL20570855 0.75 RXFP1 (0.41) MAPK1LMNAALDH1A1
SCHEMBL23948513 0.75 MEN1 (0.33) TSHRLMNAMEN1KMT2AALDH1A1
SCHEMBL10941455 0.74
SCHEMBL9038459 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2024-06-27 US disclosed
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2024-06-27 US disclosed
US-11701427-B2 Diels-alder conjugation methods REGENERON PHARMACEUTICALS, INC. (US) 2023-07-18 US disclosed
US-11701427-B2 Diels-alder conjugation methods REGENERON PHARMACEUTICALS, INC. (US) 2023-07-18 US disclosed
WO-2021211984-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS GLUL, TGM2, GLS TAAR1 3571/4885KDM4E 1011/4885ATM 3716/4885
US-11701427-B2 Diels-alder conjugation methods GLUL, TGM2, GLS TAAR1 3571/4885KDM4E 1011/4885ATM 3716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.